0000000000959292

AUTHOR

K. Haustermans

0000-0003-0364-682x

showing 4 related works from this author

The diagnosis and management of gastric cancer: Expert discussion and recommendations from the 12th ESMO/World Congress on Gastrointestinal Cancer, B…

2011

Well-recognized experts in the field of gastric cancer discussed during the 12th European Society Medical Oncology (ESMO)/World Congress Gastrointestinal Cancer (WCGIC) in Barcelona many important and controversial topics on the diagnosis and management of patients with gastric cancer. This article summarizes the recommendations and expert opinion on gastric cancer. It discusses and reflects on the regional differences in the incidence and care of gastric cancer, the definition of gastro-esophageal junction and its implication for treatment strategies and presents the latest recommendations in the staging and treatment of primary and metastatic gastric cancer. Recognition is given to the ne…

Continuous infusionComputer assisted radiotherapyFolic acidFluorodeoxyglucose f 18Gimeracil plus oteracil potassium plus tegafurInfection controlIntensity modulated radiation therapyDocetaxelCancer stagingMetastatic gastric cancerRisk FactorsPrevalenceDrug fatalityOverall survivalNeoplasm MetastasisPriority journalddc:616Conference paperdigestive oral and skin physiologyFolinic acidHematologyPrognosisOxaliplatinNuclear magnetic resonance imagingBevacizumabSurvival RateOncologyCyanocobalaminPractice Guidelines as TopicDrug dose reductionFluorouracilEsophageal adenocarcinomaHumanPositron emission tomographymedicine.medical_specialtyNeutropeniaStomach cancerStomach neoplasmsMEDLINESide effectStomach adenocarcinomaPatient careIrinotecanHelicobacter infectionPrimary tumorEndoscopic echographyAdvanced cancerEndoscopic mucosal resectionComputer assisted tomographyStomach Neoplasms/*diagnosis/pathology/*therapymedicineHumansGenetic Predisposition to DiseaseGastrointestinal cancerPhase 3 clinical trial (topic)Intensive care medicineSurvival ratePlaceboCapecitabineEpirubicinCa 19-9 antigenStomach Neoplasms/diagnosis/pathology/therapyHelicobacter pyloribusiness.industryCancerTrastuzumabCardiovascular riskmedicine.diseaseCancer susceptibilitydigestive system diseasesSurgeryClinical trialMetastasis potentialExpert opinionMeta analysis (topic)Cancer adjuvant therapyCarcinoembryonic antigenLower esophagus sphincterCisplatinCaloric intakebusinessCancer incidenceRegional differencesAnnals of Oncology
researchProduct

EURECCA colorectal: multidisciplinary mission statement on better care for patients with colon and rectal cancer in Europe

2013

Contains fulltext : 125368.pdf (Publisher’s version ) (Closed access) BACKGROUND: Care for patients with colon and rectal cancer has improved in the last twenty years however still considerable variation exists in cancer management and outcome between European countries. Therefore, EURECCA, which is the acronym of European Registration of cancer care, is aiming at defining core treatment strategies and developing a European audit structure in order to improve the quality of care for all patients with colon and rectal cancer. In December 2012 the first multidisciplinary consensus conference about colon and rectum was held looking for multidisciplinary consensus. The expert panel consisted of…

Cancer ResearchDelphi TechniqueColorectal cancerDelphi methodPhysician's Practice PatternsGUIDELINESSTAGESurgical oncologyMinimal invasive surgeryTeams in the workplacePractice Patterns Physicians'Rectal cancerCooperative BehaviorSettore MED/36 - DIAGNOSTICA PER IMMAGINI E RADIOTERAPIAddc:616Neoadjuvant radiotherapyMultidisciplinary teamTranslational research Tissue engineering and pathology [ONCOL 3]Total mesorectal excisionQuality assuranceColon cancerNeoadjuvant chemoradiotherapyEuropeColon cancer; Consensus; Delphi method; Minimal invasive surgery; Multidisciplinary team; Neoadjuvant chemoradiotherapy; Neoadjuvant radiotherapy; Quality assurance; Rectal cancerTreatment OutcomeOncologySURVIVALGuideline AdherenceColorectal NeoplasmsEuropaEUROCARECare of the sickCOUNTRIESmedicine.medical_specialtyMARGINEvidence-based practiceConsensusDelphi methodAuditDIAGNOSISSDG 3 - Good Health and Well-beingCàncer colorectalTreball en equipmedicineHumansCura dels malaltsPREOPERATIVE RADIOTHERAPYQuality of Health CarePatient Care Teambusiness.industryTOTAL MESORECTAL EXCISIONCancerAuditmedicine.diseaseColorectal cancerSurgeryOncology nursingFamily medicineREGISTRYInterdisciplinary Communicationbusiness
researchProduct

EURECCA colorectal: multidisciplinary management: European consensus conference colon & rectum.

2014

Contains fulltext : 137861.pdf (Publisher’s version ) (Closed access) BACKGROUND: Care for patients with colon and rectal cancer has improved in the last 20years; however considerable variation still exists in cancer management and outcome between European countries. Large variation is also apparent between national guidelines and patterns of cancer care in Europe. Therefore, EURECCA, which is the acronym of European Registration of Cancer Care, is aiming at defining core treatment strategies and developing a European audit structure in order to improve the quality of care for all patients with colon and rectal cancer. In December 2012, the first multidisciplinary consensus conference about…

Cancer ResearchQuality Assurance Health CareColorectal cancerCancer development and immune defence Radboud Institute for Molecular Life Sciences [Radboudumc 2]Delphi methodSurgical oncologyFAMILIAL ADENOMATOUS POLYPOSISTumours of the digestive tract Radboud Institute for Molecular Life Sciences [Radboudumc 14]MedicineSHORT-COURSE RADIOTHERAPYRectal cancerQuality assurance; Colon cancer; Rectal cancer; Multidisciplinary teams; Consensus; Delphi method; Audit; Neoadjuvant treatment; Adjuvant treatment; SurgerySettore MED/36 - DIAGNOSTICA PER IMMAGINI E RADIOTERAPIADisease ManagementPHASE-III TRIALRANDOMIZED CONTROLLED-TRIALNeoadjuvant TherapyQuality assuranceColon cancerEuropemedicine.anatomical_structureTreatment OutcomeOncologyTRANSANAL ENDOSCOPIC MICROSURGERYColonic NeoplasmsPractice Guidelines as TopicHYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPYmedicine.medical_specialtyNeoadjuvant treatmentEvidence-based practiceConsensusLYMPH-NODE EVALUATIONDelphi methodRectumAuditSDG 3 - Good Health and Well-beingHumansCIRCUMFERENTIAL RESECTION MARGINddc:610business.industryRectal NeoplasmsTOTAL MESORECTAL EXCISIONCancerLONG-TERM SURVIVALAuditAdjuvant treatmentmedicine.diseaseSurgeryOncology nursingFamily medicineSurgeryMultidisciplinary teamsbusiness
researchProduct

Molecular markers and biological targeted therapies in metastatic colorectal cancer: expert opinion and recommendations derived from the 11th ESMO/Wo…

2010

The article summarizes the expert discussion and recommendations on the use of molecular markers and of biological targeted therapies in metastatic colorectal cancer (mCRC), as well as a proposed treatment decision strategy for mCRC treatment. The meeting was conducted during the 11th ESMO/World Gastrointestinal Cancer Congress (WGICC) in Barcelona in June 2009. The manuscript describes the outcome of an expert discussion leading to an expert recommendation. The increasing knowledge on clinical and molecular markers and the availability of biological targeted therapies have major implications in the optimal management in mCRC. 21 Suppl 6 vi1 10

OncologyColorectal cancermedicine.medical_treatmentBraf proteinGastroenterologyMetastasisDrug antagonismTargeted therapyMetastasisAntineoplastic agentsPathologyConference paperBiological markersPredictive markerHematologyPrognosisChemotherapy regimenAntineoplastic agentOncologyProto-oncogene proteinsRas proteinHumanReceptormedicine.medical_specialtyNeoplasm metastasisRas proteinsMEDLINEOncoproteinColorectal neoplasmsProto-oncogene proteins b-rafInternal medicineGeneticsmedicineHumansGastrointestinal cancerColorectal tumorB raf kinaseEpidermal growth factor receptorKras proteinbusiness.industryEpidermal growth factorCancermedicine.diseasedigestive system diseasesBiological markerMetabolismSpainMutationCarcinoembryonic antigenMicrosatellite instabilitybusinessAnnals of Oncology
researchProduct